Company intelligence / Profile preview

NeuroVia

San Francisco, California, United Statesneurovia.org ↗

Ownership: Private
Development stage: Preclinical

Overview

NeuroVia developed NV1205, an orally administered small molecule for X-linked adrenoleukodystrophy. The drug was shown to be safe and well-tolerated in Phase 1 clinical studies. The company aimed to address significant unmet needs in rare CNS disorders but is now closed.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Novartis VenturesSanofi Genzyme Ventures

Beyond the preview

Go deeper on NeuroVia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroVia.

Explore the full profile